导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.10% | 1913/4773 |
| 近一周 | -0.05% | 890/5465 |
| 近一月 | 5.03% | 71/5421 |
| 近一季 | 5.99% | 280/5231 |
| 近半年 | 5.25% | 809/4920 |
| 近一年 | 4.21% | 1901/4394 |
| 近两年 | 39.82% | 1910/2954 |
| 近三年 | 48.86% | 582/2253 |
| 成立以来 | 73.71% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.72% 2879/4961 |
-8.16% 3847/5312 |
- - |
- - |
| 2025 | 10.92% 2778/4813 |
2.61% 1311/3635 |
11.65% 144/4076 |
-8.44% 4035/4524 |
5.74% 402/4813 |
| 2024 | 39.44% 24/3463 |
10.09% 76/2808 |
6.87% 116/3014 |
12.44% 2346/3129 |
5.41% 610/3463 |
| 2023 | -2.52% 584/2656 |
-2.42% 1979/2280 |
1.85% 195/2385 |
4.73% 131/2515 |
-6.34% 1727/2655 |
| 2022 | -4.09% 81/2207 |
2.34% 57/1919 |
-1.32% 1706/2016 |
-8.08% 167/2113 |
3.32% 722/2208 |
| 2021 | -0.97% 774/1822 |
10.18% 44/1255 |
-2.53% 1210/1330 |
-7.16% 1028/1466 |
-0.68% 1266/1822 |
| 2020 | -0.25% 941/1250 |
-13.80% 940/1028 |
2.05% 979/1067 |
4.41% 955/1164 |
8.61% 664/1184 |
| 2019 | 27.50% 543/1092 |
14.88% 694/739 |
2.42% 82/788 |
1.66% 378/850 |
6.59% 586/918 |
| 2018 | -12.15% 81/834 |
- - |
-10.44% 313/631 |
11.00% 9/660 |
-9.62% 154/682 |
| 2017 | 18.08% 211/714 |
- - |
- - |
- - |
- - |
| 2016 | -2.60% 135/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证银行ETF联接A VS. 长安沪深300非周期A(740101) |